Dr. Martens plc (LON:DOCS – Get Free Report) insider Robert Hanson purchased 96,000 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were acquired at an average price of GBX 79 per share, for a total transaction of £75,840.
Dr. Martens Price Performance
Dr. Martens stock opened at GBX 78.30 on Monday. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. The firm has a market cap of £756.65 million, a P/E ratio of 46.06, a P/E/G ratio of 6.40 and a beta of 0.11. The business’s fifty day moving average is GBX 86.75 and its two-hundred day moving average is GBX 82.07. Dr. Martens plc has a 52 week low of GBX 43.02 and a 52 week high of GBX 100.87.
Dr. Martens (LON:DOCS – Get Free Report) last released its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. Equities research analysts forecast that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on Dr. Martens
Dr. Martens Company Profile
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.
See Also
- Five stocks we like better than Dr. Martens
- Business Services Stocks Investing
- Rubrik’s Massive Rebound: Why the Next Leg Higher Could Be Fast
- Using the MarketBeat Dividend Yield Calculator
- Five Below and Dollar Tree Earnings Signal a Shopper Shift
- Overbought Stocks Explained: Should You Trade Them?
- Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?
Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.
